SCHEMBL7723892

SCHEMBL7723892

CC(=O)SCCN(CCC1CCCCC1)C(=O)NCc1csc(C)n1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.35
▸ SLC5A7 Q9GZV3 1/20 0.35
▸ MAPK14 Q16539 1/20 0.35
▸ SMN1; SMN2 Q16637 5/20 0.34
▸ HPGD P15428 5/20 0.34
▸ NPC1 O15118 3/20 0.34
▸ RAB9A P51151 3/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ MAPT P10636 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.33
▸ CHRM4 P08173 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ ALOX5 P09917 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ TP53 P04637 1/20 0.32
▸ PDE10A Q9Y233 1/20 0.32
▸ CASR P41180 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7725059 0.99 CYP1A2 (0.35) CYP1A2SLC5A7MAPK14SMN1; SMN2HPGD
SCHEMBL7729404 0.87 MAPK14 (0.37) CYP1A2SLC5A7MAPK14SMN1; SMN2HPGD
SCHEMBL7725008 0.80 KMT2A (0.41) MAPK14SMN1; SMN2HPGDNPC1RAB9A
SCHEMBL7723011 0.79 EPHX1 (0.45) CYP1A2SMN1; SMN2ALDH1A1MAPTTP53
SCHEMBL7729389 0.79 EPHX1 (0.45) CYP1A2SMN1; SMN2ALDH1A1MAPTTP53
SCHEMBL7719582 0.79 EPHX1 (0.45) CYP1A2SMN1; SMN2ALDH1A1MAPTTP53
Hydrochloric Acid SCHEMBL7719584 0.78 EPHX1 (0.44) CYP1A2SMN1; SMN2ALDH1A1MAPTTP53
Hydrochloric Acid SCHEMBL7725020 0.78 EPHX1 (0.44) CYP1A2SMN1; SMN2ALDH1A1MAPTTP53
SCHEMBL7725052 0.78 NAMPT (0.43) RAB9AALDH1A1MAPTTP53
Hydrochloric Acid SCHEMBL7721942 0.77 NAMPT (0.42) RAB9AALDH1A1MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1147469-C Novel urea derivatives bearing nitrogenous aromatic heterocycles ������ҩ��ʽ���� 2004-04-28 — — CN disclosed
US-6420398-B2 FOR TREATING AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS; 4-(3-(2-(ACETYLTHIO)ETHYL)-3-(2-CYCLOHEXYLETHYL)-UREIDOMETHYL)-1 -METHYLPYRIDINIUM IODIDE, FOR EXAMPLE; INHIBIT PRODUCTION OF TUMOR NECROSIS FACTOR ALPHA (TNF-A) SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 — — US disclosed
US-20010041725-A1 Novel urea derivatives having nitrogen aromatic heterocycle SANTEN PHARMACEUTICAL CO., LTD. (JP) 2001-11-15 — — US disclosed
EP-1103543-A1 NOVEL UREA DERIVATIVES BEARING NITROGENOUS AROMATIC HETEROCYCLES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2001-05-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010041725-A1 Novel urea derivatives having nitrogen aromatic heterocycle TNF, UACA, HRH4 CYP1A2 1721/4885SLC5A7 3516/4885MAPK14 1578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback